Morningstar Investment Services LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 59.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,343 shares of the medical research company's stock after selling 32,336 shares during the period. Morningstar Investment Services LLC's holdings in IQVIA were worth $3,939,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Sowell Financial Services LLC bought a new position in shares of IQVIA during the 1st quarter worth $305,000. Mather Group LLC. boosted its position in IQVIA by 83.5% during the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after purchasing an additional 350 shares in the last quarter. Park Avenue Securities LLC boosted its position in IQVIA by 40.4% during the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after purchasing an additional 1,562 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after purchasing an additional 3,398 shares in the last quarter. Finally, Blair William & Co. IL boosted its position in IQVIA by 42.0% during the fourth quarter. Blair William & Co. IL now owns 5,742 shares of the medical research company's stock valued at $1,128,000 after purchasing an additional 1,699 shares in the last quarter. Institutional investors own 89.62% of the company's stock.
IQVIA Trading Down 1.5%
IQV traded down $2.37 during mid-day trading on Friday, hitting $160.88. 2,312,787 shares of the stock were exchanged, compared to its average volume of 1,678,075. The firm's fifty day moving average is $152.90 and its two-hundred day moving average is $170.85. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The company has a market cap of $27.83 billion, a PE ratio of 21.92, a PEG ratio of 1.78 and a beta of 1.30.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the business earned $2.54 EPS. IQVIA's revenue was up 2.5% on a year-over-year basis. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Analyst Ratings Changes
IQV has been the subject of a number of research analyst reports. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Robert W. Baird reduced their price objective on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Mizuho reduced their price objective on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, HSBC cut IQVIA from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $222.45.
Check Out Our Latest Stock Analysis on IQVIA
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
